Programme Thesis
This NIH X01 programme provides access to the Contraceptive Development Program's biological testing facilities for researchers developing novel contraceptives or reproductive health interventions. It exists to accelerate preclinical development by offering specialized in vitro and in vivo assays, pharmacokinetic studies, and safety/toxicology evaluations at no cost to the investigator, with the goal of advancing promising leads toward clinical trials.
Selection Criteria
Scientific merit and innovation of the proposed contraceptive or reproductive health intervention; feasibility and appropriateness of the proposed testing plan; qualifications and experience of the investigator(s); potential impact on the field of contraception and reproductive health; alignment with NIH priorities for expanding contraceptive options (e.g., male contraceptives, non-hormonal methods, long-acting reversible contraceptives). Reviewers use a 1-9 scoring scale; applications must demonstrate a clear hypothesis, well-defined milestones, and a realistic timeline for testing.
Past Winners / Cohort Profiles
Past awardees are typically academic researchers (PhD, MD, or equivalent) at U.S. institutions with established expertise in reproductive biology, pharmacology, or medicinal chemistry. Examples include investigators from universities like the University of Washington, Oregon Health & Science University, and the Population Council. Profiles often include prior publications in contraception or reproductive health, preliminary data on a lead compound or device, and a collaborative team with access to animal models or clinical samples. No specific named winners are listed on the programme page.
Ideal Candidate Fingerprint
The ideal applicant is a mid-career or senior U.S.-based academic researcher (PhD or MD) with a strong track record in contraceptive development, reproductive biology, or medicinal chemistry. They have a well-characterized lead compound, device, or biologic with compelling preliminary data (e.g., in vitro efficacy, acceptable safety profile) and a clear plan for utilizing the NIH's core testing services (e.g., pharmacokinetics, toxicology, efficacy in animal models) to advance toward an IND application.
Recommended Framing
Eniola should pivot his CCT model and computational platforms (IMPRINT, TOPOLOGIX) toward a reproductive health application—for example, using his addiction-liability screening tool to identify non-hormonal contraceptive targets that avoid reward-memory encoding pathways, or repurposing his TDA platform to predict off-target effects of novel contraceptive compounds on neural reward circuits. He must partner with a U.S.-based academic collaborator (e.g., Kent Berridge at Michigan or a reproductive biologist) who can serve as the PI and provide access to the testing facility, while Eniola contributes computational expertise and the CCT framework as a novel screening methodology. The proposal should emphasize how his computational models can de-risk and accelerate the preclinical testing pipeline for contraceptives, aligning with NIH's interest in innovative, non-hormonal approaches.
Watch Out
Eniola is not eligible as a sole applicant because this X01 mechanism requires the PI to be affiliated with a U.S. institution; he must secure a U.S.-based collaborator as the primary applicant. His background in addiction neuroscience, not reproductive biology, may be seen as a mismatch unless he clearly frames the CCT model's relevance to contraceptive target discovery. He has no preliminary data in contraception, which is a significant competitive disadvantage. The programme does not provide funding—only access to testing facilities—so Eniola would need separate funding for his own time and travel.